Read by QxMD icon Read


Tatiane Fernandes Farias, Karina da Silva Aguiar, Inajara Rotta, Klezia Morais da Silva Belletti, Juliane Carlotto
Objective: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. Methods: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical pharmacy service, respectively. This service consisted of an antineoplastic prescription validation (analysis of patients' characteristics, laboratory tests, compliance with the therapeutic protocol and with pharmacotechnical parameters)...
July 2016: Einstein
Patrícia Fernanda Saboya Ribeiro, Luiz Fernandao Kubrusly, Paulo Afonso Nunes Nassif, Irma Cláudia Saboya Ribeiro, Andressa de Souza Bertoldi, Venessa Caroline Batistão
Background: The Helicobacter pylori infection (HP) is related to the development of gastric lesions and lymphoma; however, it is not known if there is a relation with gastroesophageal reflux disease and reflux esophagitis. Aim: To evaluate HP's relationship with esophagitis in patients undergoing upper endoscopy. Methods: Observational, retrospective and cross-sectional study, being evaluated 9576 patients undergoing outpatient endoscopic examination during the period between January and December 2015...
July 2016: Arquivos Brasileiros de Cirurgia Digestiva: ABCD, Brazilian Archives of Digestive Surgery
Lidia Maroñas-Jiménez, Sara Burillo-Martínez, Fátima Tous-Romero, Jose Luis Rodríguez-Peralto, Javier Ortiz de Frutos, Pablo Luis Ortiz-Romero
The growing use of anti-TNF drugs during the last years has reopened the discussion about the possible increased risk of developing non-Hodgkin lymphoma in patients with such type of treatments. We present our clinical experience and critical opinion about the current situation of such issue regarding cutaneous T-cell lymphomas.El creciente uso de fármacos anti-TNF durante los últimos años ha reabierto el debate sobre el posible aumento de riesgo de linfomas no Hodgkin en los pacientes con este tipo de tratamientos...
2016: Dermatology Online Journal
Lidiane Miotto Barretta, Lúcia Marinilza Beccaria, Cláudia Bernardi Cesarino, Maria Helena Pinto
OBJECTIVE: to identify the model, average length of stay on site and complications of central venous catheter in patients undergoing transplant of hematopoietic stem cells and verify the corresponding relationship between the variables: age, gender, medical diagnosis, type of transplant, implanted catheter and insertion site. METHOD: a retrospective and quantitative study with a sample of 188 patients transplanted records between 2007 and 2011. RESULTS: the majority of patients used Hickman catheter with an average length of stay on site of 47...
June 7, 2016: Revista Latino-americana de Enfermagem
Eva González-Barca, Miguel A Canales, Antonio Salar, Secundino Ferrer, Eva Domingo-Domenech, María-Jesús Vidal, Carlos Grande, Joan Bargay, Santiago Gardella, Albert Oriol, Javier Briones, Javier García-Frade, Jose L Bello, Jose J Sánchez-Blanco, Francisco Javier Peñalver, Jose Francisco Tomás, Antonio Asensio, Andrés López, Dolores Caballero
BACKGROUND/AIMS: Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients. Currently, the standard regimen is R-CHOP every 21 days. METHODS: This is a phase II clinical trial of treatment with 6 cycles of R-CHOP-14 with pegfilgrastim support in 2 populations of previously untreated DLBCL patients aged ≥65 years (n = 73) or <65 years (n = 51) with low-risk International Prognostic Index scores (0-2)...
2016: Acta Haematologica
Claudio Bianchi, Tommaso Bianchi
No abstract text is available yet for this article.
January 2016: La Medicina del Lavoro
J Huerta-Guzman, G Ignacio-Ibarra, J Talavera-Piña, J Sierra-Ramírez, I Contreras-Hernandez
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Carlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, Francisco Javier Díaz, Eva González-Barca, Raquel de Oña, Carlos Grande, Juan Manuel Sancho, María Flor García-Álvarez, Blanca Sánchez-González, Francisco Javier Peñalver, Jimena Cannata, Manuel Espeso, María José Requena, Santiago Gardella, Soledad Durán, Ana Pilar González, Ana Alfonso, María Dolores Caballero
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, showing a highly variable outcome. In patients with DLBCL relapsed/refractory to first-line treatment with rituximab the usefulness of the revised International Prognostic Index (R-IPI) as a prognostic tool remains unexplored. Some biological parameters (B-cell lymphoma 6 [Bcl-6], Bcl-2, p53, and multiple myeloma 1 [MUM1]) and blood populations (lymphocyte and monocyte counts) have been described as International Prognostic Index-independent prognostic factors...
July 2015: Clinical Lymphoma, Myeloma & Leukemia
Eva González-Barca, Miguel Canales, Montse Cortés, M Jesus Vidal, Antonio Salar, Albert Oriol, Joan Bargay, José L Bello, José J Sánchez, José F Tomás, Eva Donato, Secundino Ferrer, Dolores Caballero
OBJECTIVE: The predictive value of interim PET/computed tomography (I-PET/CT) in diffuse large B-cell lymphoma (DLBCL) is controversial. Our aim was to evaluate the predictive value of I-PET/CT for an event-free survival. PATIENTS AND METHODS: We analyzed patients with DLBCL included in a prospective clinical trial who were treated with six cycles of dose-dense R-CHOP followed by pegfilgrastim and who had undergone an I-PET/CT (after two cycles) and a final PET [F-PET/CT (60 days after the sixth cycle)]...
October 2013: Nuclear Medicine Communications
M A Ramírez-Crescencio, L Velásquez-Pérez, María Antonieta Ramírez-Crescencio, Leora Velásquez-Pérez
OBJECTIVE: The aim of this study was to identify the main neurological conditions associated with HIV/AIDS in Mexican patients treated at the National Institute of Neurology and Neurosurgery (NINN) in Mexico city, the main referral center for patients with disorders of the central and peripheral nervous system. METHODS: An observational, transversal and descriptive analysis was performed. We reviewed the databases from the Department of Epidemiology and the medical records of patients with AIDS seen during the period from January 1st, 1995 to December 31, 2009...
August 2013: Clinical Neurology and Neurosurgery
Marco Antonio Alcocer Gamba, Salvador León González, Eliodoro Castro Montes, Luis Martín Loarca Piña, Leslie Marisol Lugo Gavidia, Enrique García Hernández, Ulises González Galindo, Miguel Isaías Paredes Serrano
Cardiac tumors are rare entities in clinical practice, with an incidence of 0.05%. Approximately 75% are benign and 25% malignant. Among these, Lymphomas are uncommon, representing about 0.25%. The non-Hodgkin lymphomas can occur in extranodal tissues in 20% of the cases and 80% of these non-Hodgkin lymphomas are composed of diffuse B cells. The extranodal presentation is most frequent in young adults, with a high degree of malignancy and rapid growth. It can present with primary infiltration of various organs; cardiac involvement occurs in 20 to 28% of cases, usually located in the right chambers and with nonspecific symptoms, depending on the location and extent of the tumor...
September 2012: Investigación Clínica
Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats Brune, Jacob Passweg, Rodrigo Martino, David Valcárcel, Joan Besalduch, Rafael Duarte, Angel León, Maria Jesus Pascual, Ana García-Noblejas, Lucia López Corral, Bianca Xicoy, Jordi Sierra, Norbert Schmitz
BACKGROUND: Although Hodgkin's lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line chemotherapy or even after high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic stem cell transplantation in this setting. DESIGN AND METHODS: In this phase II study 92 patients with relapsed Hodgkin's lymphoma and an HLA-identical sibling, a matched unrelated donor or a one antigen mismatched, unrelated donor were treated with salvage chemotherapy followed by reduced intensity allogeneic transplantation...
February 2012: Haematologica
Maria Rosário Giraldes
Nuclear imaging has used initially anatomic and volumetric technologies as CT or MRI. In recent years new dimensions of non invasive studies, as PET, have shown a higher utility in the effectiveness of the treatment. The evaluation of need must be done according to a principle of Horizontal Equity, equal treatment for equal need and of a principle of Vertical Equity, Different treatment, at regional level, according to each hospital level. The evaluation of need has been made according to the Potential Demand by Potential User Groups: diabetes, type 2, (50 years and more); screening colorectal (50 years and more); morbidity by cancer; surgery of lung cancer; cardiology; heart surgery; acute chest pain in the emergency department...
March 2010: Acta Médica Portuguesa
J M Calvo-Villas, A Martín, E Conde, A Pascual, I Heras, R Varela, J de la Rubia, M J Ramirez, J L Díez-Martín, C Panizo, M J Rodríguez-Salazar, M J Pascual, E M Donato, E González-Barca, M D Caballero
BACKGROUND: We have investigated if rituximab-based salvage regimens improve response rates and survival of patients with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: We have retrospectively analyzed 82 patients with DLBCL who received salvage therapy for relapse or progression after ASCT. Patients were divided into two groups, according to whether rituximab-based salvage regimens were given (n = 42, 'R-' group) or not (n = 40, 'R+' group) after ASCT...
September 2010: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Pilar Miralles, Juan Berenguer, Josep-Maria Ribera
With the widespread use of highly active antiretroviral therapy (HAART) the incidence of systemic non-Hodgkin lymphoma (NHL) in patients infected with the Human Immunodeficiency Virus (HIV) has declined. HAART has also modified the clinical manifestations of these tumors, with a lower frequency of involvement of the central nervous system (CNS). Currently, the frequency of meningeal involvement at the time of diagnosis of NHL in HIV-infected patients varies between 3% and 5%. These figures are similar to those observed among immunocompetent hosts...
September 18, 2010: Medicina Clínica
Alejandro Martín, Eulogio Conde, Montserrat Arnan, Miguel A Canales, Guillermo Deben, Juan M Sancho, Rafael Andreu, Antonio Salar, Pedro García-Sanchez, Lourdes Vázquez, Sara Nistal, María-José Requena, Eva M Donato, José A González, Angel León, Concepción Ruiz, Carlos Grande, Eva González-Barca, María-Dolores Caballero
BACKGROUND: The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence of prior exposure to rituximab on response rates and survival in patients with diffuse large B-cell lymphoma treated with rituximab plus etoposide, cytarabine, cisplatinum and methylprednisolone (R-ESHAP). DESIGN AND METHODS: We retrospectively analyzed 163 patients with relapsed or refractory diffuse large B-cell lymphoma who received R-ESHAP as salvage therapy with a curative purpose...
December 2008: Haematologica
(no author information available yet)
INTRODUCTION: In patients with refractory or recurrent follicular lymphoma responding to induction therapy with CHOP or rituximab + CHOP, maintenance treatment with rituximab compared to the "observation" option improves both overall survival and progression-free survival. OBJECTIVE: Estimate whether maintenance treatment with rituximab is a cost-effective intervention compared to the clinical practice of "observing" its evolution. METHOD: HASH(0x454ec48) POPULATION: the EORTC 20981 clinical trial population...
January 2008: Farmacia Hospitalaria
M J Herráiz Bayod, M Elorz Carlón, M A Idoate
We report the case of a fiftyone-year-old woman with a past medical history of Linfoma no Hodking and a gastric adenocarcinoma with signet ring cells. She came to our institution with a twenty month history of dysnea secondary to pleural effussion, bilateral lower extremity edema and probably had ascitis. On CT and US two bilateral pelvic masses were found and biopsied. The anatomopathological analysis showed bilateral ovarian implants from signet ring cell adenocarcinoma (Krukenberg tumor). This patient developed a PseudoMeigs syndrome consisting on malignant ovarian tumor asociated with ascitis and pleural effusion without malignant cells...
July 2007: Revista de Medicina de la Universidad de Navarra
Reyes Arranz, Eulogio Conde, Carlos Grande, Maria Victoria Mateos, Marco Gandarillas, Carmen Albo, Juan J Lahuerta, José M Fernández-Rañada, Miguel T Hernández, Natalia Alonso, José A García Vela, Sebastián Garzón, José Rodríguez, Dolores Caballero et al.
OBJECTIVES: The role of high-dose therapy and autologous stem-cell transplantation (HDT/ASCT) in the up-front treatment of poor-risk aggressive lymphoma is still unknown. We conducted a prospective multi-centre trial with dose-escalated CHOP (MegaCHOP) and tailored intensification prior to HDT/ASCT according to early response assessed by CT and gallium scan (Ga67S). PATIENTS AND METHODS: Eighty-six patients with newly diagnosed and Ga-67 avid aggressive B-cell lymphoma received MegaCHOP for three courses and were evaluated for response by CT and Ga67S...
March 2008: European Journal of Haematology
Eva González-Barca, Eva Domingo-Domenech, Francisco Javier Capote, Jose Gómez-Codina, Antonio Salar, Alicia Bailen, Jose-María Ribera, Andres López, Javier Briones, Andres Muñoz, Maite Encuentra, Alberto Fernández de Sevilla, , et al.
BACKGROUND AND OBJECTIVES: The elective treatment of patients with post-transplant lymphoproliferative disorders is controversial. The purpose of this trial was to evaluate the efficacy of treatment with extended doses of rituximab adapted to the response in patients with post-transplant lymphoproliferative disorders after solid organ transplantation. DESIGN AND METHODS: This was a prospective, multicenter, phase II trial. Patients were treated with reduction of immunosuppression and four weekly infusions of rituximab...
November 2007: Haematologica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"